tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OPT Stock Latest News

Opthea Limited Reports Improved Financial Results Amid R&D Challenges
Company AnnouncementsOpthea Limited Reports Improved Financial Results Amid R&D Challenges
2d ago
6K
OPT
Opthea terminates COAST trial, announces ShORe trial misses endpoint
PremiumThe Fly
Opthea terminates COAST trial, announces ShORe trial misses endpoint
5M ago
OPT
Opthea downgraded to Perform from Outperform at Oppenheimer
PremiumThe Fly
Opthea downgraded to Perform from Outperform at Oppenheimer
5M ago
OPT
Opthea downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
Opthea downgraded to Market Perform from Outperform at Leerink
5M ago
OPT
Opthea cut to Market Perform at Leerink on failed sozinibercept trial
PremiumThe Fly
Opthea cut to Market Perform at Leerink on failed sozinibercept trial
5M ago
OPT
Opthea double downgraded to Underperform from Buy at Jefferies
PremiumThe FlyOpthea double downgraded to Underperform from Buy at Jefferies
5M ago
OPT
Opthea downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Opthea downgraded to Neutral from Buy at H.C. Wainwright
5M ago
OPT
CoreWeave initiated, Carvana upgraded: Wall Street’s top analyst calls
Premium
The Fly
CoreWeave initiated, Carvana upgraded: Wall Street’s top analyst calls
5M ago
AJG
AON
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure
PremiumRatings
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure
5M ago
OPT
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty
PremiumRatings
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty
5M ago
OPT
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns
PremiumCompany Announcements
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns
5M ago
6K
OPT
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors
PremiumThe Fly
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors
5M ago
OPT
Opthea Ltd (ADR) trading halted, news pending
PremiumThe FlyOpthea Ltd (ADR) trading halted, news pending
6M ago
OPT
Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 Target
Premium
Ratings
Opthea Limited: Promising Clinical Trials and Strong Financial Position Support Buy Rating with $13 Target
6M ago
OPT
Opthea announces Phase 2b Wet AMD publication
Premium
The Fly
Opthea announces Phase 2b Wet AMD publication
6M ago
OPT
Opthea Limited Reports Increased Losses Amid Clinical Advancements
PremiumCompany Announcements
Opthea Limited Reports Increased Losses Amid Clinical Advancements
6M ago
OPT
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
PremiumThe Fly
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
6M ago
OPT
Opthea announces anticipated milestones
PremiumThe Fly
Opthea announces anticipated milestones
6M ago
OPT
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
PremiumRatings
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment
6M ago
OPT
Opthea completes drug product PPQ campaign
PremiumThe FlyOpthea completes drug product PPQ campaign
6M ago
OPT
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
Premium
Ratings
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
6M ago
OPT
Opthea completes COAST final week 52 patient visit
Premium
The Fly
Opthea completes COAST final week 52 patient visit
6M ago
OPT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >